| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | In appraisal |
| Process | STA Standard |
| ID number | 6340 |
Provisional Schedule
| Draft guidance | 26 November 2024 - 17 December 2024 |
Project Team
| Project lead | Louise Jafferally |
Email enquiries
- If you have any queries please email TATeam4@nice.org.uk
| External Assessment Group | Southampton Health Technology Assessment Centre (SHTAC), University of Southampton |
Stakeholders
| Companies sponsors | Merck Sharp & Dohme (molnupiravir) |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Cardiothoracic Transplant Patient Group |
| Kidney Research UK | |
| Professional groups | Association of Cancer Physicians |
| British Society for Immunology | |
| Cancer Research UK | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| UK Clinical Pharmacy Association | |
| UK Renal Pharmacy Group | |
| Associated public health groups | None |
| Comparator companies | Gilead Sciences (remdesivir) |
| GlaxoSmithKline (sotrovimab) | |
| Pfizer (nirmatrelvir plus ritonavir) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 November 2024 | Committee meeting |
| 12 April 2024 | Invitation to participate |
| 12 April 2024 | As with previous technology appraisals of medicines for COVID-19, NICE is collaborating with the Scottish Medicines Consortium. See appendix 1 of the Final Scope for more details. |
| 06 November 2023 - 04 December 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 06 September 2023 | In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual